John Teerlink News Today

New Board would recognize evolution of cardiology into distinct medical specialty WASHINGTON, Sept. 21, 2023 /PRNewswire/ -- Many of the nation's most prominent cardiovascular organizations, representing tens of

No one interviewed by TCTMD fell seriously ill, most had plans to attend future meetings. All felt conflicted about the path forward.

/PRNewswire/ -- The Heart Failure Society of America (HFSA) will host the HFSA Annual Scientific Meeting September 30-October 3, 2022, at the Gaylord National...

ROCKVILLE, Md., June 9, 2022 /PRNewswire/ -- The Heart Failure Society of America (HFSA) will host the HFSA Annual Scientific Meeting September 30...

In what might prove the swan song for ERAs in HF, SERENADE tried to exclude patients with fluid retention—to no avail.

Heart failure patients taking the investigational drug omecamtiv mecarbil, which has been previously shown to improve long-term outcomes, see little impact on their ability to exercise compared to a placebo, according to a study supported by the Duke Clinical Research Institute.

Heart failure patients taking the investigational drug omecamtiv mecarbil, which has been previously shown to improve long-term outcomes, see little impact on t

I’m running out of words and tears.

May 18, 2021 When omecamtiv mecarbil is used in patients who have chronic heart failure with reduced ejection fraction (HFrEF), the greater beneficial impact on clinical outcomes is seen in those with lower ejection fractions, a secondary analysis of the placebo-controlled GALACTIC-HF trial shows. Among the prespecified subgroups in the trial, LVEF was the strongest modifier of the treatment effect, with larger reductions in the risk of HF events or CV death observed as values fell ( P = 0.004 ...

Operator Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics First Quarter 2021 Conference Call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen-only mode. At the companys request, we will open the call for questions-and-answers after the presentation. I will now like to turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead. Dian...